Preview

Вопросы современной педиатрии

Расширенный поиск

БЕЗОПАСНОСТЬ ПРИМЕНЕНИЯ ИНГИБИТОРОВ ФАКТОРА НЕКРОЗА ОПУХОЛИ ВО ВЗРОСЛОЙ И ДЕТСКОЙ РЕВМАТОЛОГИЧЕСКОЙ ПРАКТИКЕ

Аннотация

Обзор посвящен безопасности применения анти-ФНО препаратов для лечения ревматических болезней у взрослых и у детей. Приведены данные отдельных, открытых, а также многоцентровых двойных слепых плацебоконтролируемых исследований переносимости инфликсимаба, этанерцепта, адалимумаба. Результаты исследований свидетельствуют о высокой эффективности и безопасности анти-ФНО терапии во взрослой и детской ревматологической практике.

Ключевые слова: дети, ревматоидный артрит, ювенильный артрит, ингибиторы ФНО, лечение, безопасность, инфликсимаб, адалимумаб, этанерцепт.
(Вопросы современной педиатрии. 2010;9(1):82-94)

Об авторах

Т.М. Бзарова
Научный центр здоровья детей РАМН, Москва
Россия


Е.И. Алексеева
Научный центр здоровья детей РАМН, Москва
Россия


С.И. Валиева
Научный центр здоровья детей РАМН, Москва
Россия


А.М. Алексеева
Научный центр здоровья детей РАМН, Москва
Россия


Р.В. Денисова
Научный центр здоровья детей РАМН, Москва
Россия


К.Б. Исаева
Научный центр здоровья детей РАМН, Москва
Россия


Список литературы

1. Cassidy J., Petty R. Textbook of pediatric rheumatology. 2nd end. New York: Churchill Livigstone. 2002.

2. Brenann F.M., Maini R.N., Feldman M. TNF alpha – a pivotal role in rheumatoid arthritis? Brit. J. Rheumatol. 1992; 31: 293–298.

3. Arend W.P., Dayer J.M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum. 1995; 38: 151–160.

4. Elliott M.J., Maini R.N., Feldmann M. et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993; 36: 1681–1690.

5. Elliot M.J., Maini R.N., Feldmann M. et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994; 344: 1105–1110.

6. Furst D.E., Schiff M.H., Fleischmann R.M. et al. Adahmumab, a fully human antitumor necrosis factor a monoclonal antibody and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis results of STAR (Safety Trial of Adahmumab in Rheumatoid Arthritis). J. Rheumatol. 2003; 30: 2563–2571.

7. Weinblatt M.E., Keystone E.C., Furst D.E. et al. Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate the ARMADA. Arthritis Rheum. 2003; 48 (1): 35–45.

8. Keystone E.C., Kavanaugh A.F., Sharp J.T. et al. Radiographic, clinical, and functional outcomes of treatment with adahmumab (a human antitumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy a randomized, placebo controlled, 52 week trial. Arthritis Rheum. 2004; 50: 1400–1411.

9. Van de Putte L.B., Atkins C., Malaise M. et al Efficacy and safety of adahmumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 2004; 63: 508–516.

10. Mease P.J., Gladman D.D., Ritchhn C.T. et al. Study Group Adahmumab for the treatment of patients with moderately to severely active psonatic arthritis results of a double blind, randomized, placebo controlled trial. Arthritis Rheum. 2005; 52: 3279–3289.

11. Garrison L., McDonnell N.D. Etanercept. Therapeutic use in patients with rheumatoid arthritis. Ann. Rheum. Dis. 1999; 58: 165–169.

12. Goldenberg M.M. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin. Ther. 1999; 21: 75–87.

13. Moreland L.W., Margolies G., Heck L.W. et al. Recombinant soluble tumor necrosis factor receptor fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J. Rheumatol. 1996; 23: 1849–1855.

14. Moreland L.W., Scott M.D., Baumgarther W. et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75) Fc fusion protein. New Engl. J. Med. 1997; 337: 141–147.

15. Weinblatt M., Kremer J., Bankhurst A. et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patient, in patients with rheumatoid arthritis receiving methotrexate. New Engl. J. Med. 1999; 340: 253–259.

16. Maini R.N., Breedveld F.C., Kalden J.R. et al. Therapeutic efficacy of multiplay intravenous infusion of anti-tumor necrosis factor α monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998; 41: 1552–1563.

17. Maini R.N., St. Clair E.W., Breedveld F.C. et al. Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet. 1999; 354: 932–939.

18. Lipsky P.E., van der Heijde D.M., Clair E.W. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 2000; 343: 1594–1602.

19. Bredveld F.C., Emery P., Keystone E. et al. Infliximab in active early rheumatoid arthritis. Ann. Rheum. Dis. 2004; 63: 149–155.

20. Brandt J., Kariouzov A., Listing J. et al. Six months results of a German double-blind placebo controlled, phase-III clinical trial of Etanercept in active ankylosing spondylitis. Arthritis Rheum. 2002; 46: 429.

21. Calin A., Dijkmans B., Emery P. et al. Assessments of disease activing and functionality by Enbrel treated ankylosing spondylitis patients in multicenter, placebo controlled trial. Arthritis Rheum. 2003; 48: 172.

22. Davis J.C., van der Heijde D., Braun J. et al. Etanercept (Enbrel) improves signs and symptoms of ankylosing spondylitis: results of a phase 3 multicenter clinical trial. Ann. Rheum. Dis. 2003; 62: 65.

23. Gorman J.D., Sack K.E., Davis J.C. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. New Engl. J. Med. 2002; 346: 1349–1356.

24. Van der Heijde D., Dougados M., Davic J.C. et al. The effects of etanercept on patient-reported outcomes for subjects with ankylosing spondylitis. Arthritis Rheum. 2003; 48: 174.

25. Lovell D., Giannini E., Reiff A. et al. Long term efficacy and safety of etanercept in children with polyarticular course juvenile rheumatoid arthritis. New Engl. J. Med. 2003; 48: 218–236.

26. Breedveld F.C. Weisman M.H. Kavanaugh A.F. et al. The PREMIER study a multicenter, randomized, double blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006; 54: 26–37.

27. Burmester G.R., Manette X., Montecucco C.M. et al. Adahmumab alone and in combination with disease modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann. Rheum. Dis. Published Online First 20 March 2007 doi: 10 1136/ard. 2006 066761

28. Keystone E.C., Kavanaugh A.F., Sharp J.T., Tannenbaum H., Hua Y., Teoh L.S. et al. Radiographic, clinical, and functional outcomes of treatment with adahmumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy a randomized, placebo controlled, 52 week trial. Arthritis Rheum. 2004; 50: 1400–1411.

29. Moreland L.W., Cohen S.B., Baumgartner S.W. et al. Long term safety and efficacy of etanercept in patients with rheumatoid arthritis. J. Rheumatol. 2001; 28: 1238–1244.

30. Schiff M., van de Putte L.B., Breedveld F.C. et al. Rates of infection in adahmumab rheumatoid arthritis clinical trials. Ann. Rheum. Dis. 2003; 62: 184.

31. Schiff M.H., Gelhorn A.J., Chartash E., Fischkoff S.A. Malignancies in rheumatoid arthritis (RA) clinical trials with adahmumab (HUMIRA. Arthritis Rheum. 2003; 48 (9): 700.

32. Лукина Г.В., Сигидин Я.А. Риск развития туберкулеза при использовании ингибиторов фактора некроза опухоли–ᾳ. РМЖ. 2009; 17 (21): 1438–1442.

33. Beevor C.P., Hull R., Thomas A. et al. Anti TNFa therapy reduce emergency health services usage. Ann. Rheum. Dis. 2006; 65 (II): 176.

34. Dhillon S., Lyseng–Williamson K.A., Scott L.J. Etanercept. A review of its use in the management of rheumatoid arthritis. Drugs. 2007; 67: 1211–1241.

35. Насонов Е.Л. Эффективность и безопасность ингибиторов фактора некроза опухоли–a при ревматоидном артрите. РМЖ. 2008; 16 (24): 1602–1609.

36. Бунчук Н.В. Анкилозирующий спондилит: новые возможности и перспективы фармакотерапии. Фарматека. 2006; 6: 26–31.

37. Braun J., Davis J., Dougados M. et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann. Rheum. Dis. 2006; 65 (3): 316–320.

38. Лукина Г.В., Сигидин Я.А. Безопасность терапии адалимумабом. Научно–практическая ревматология. 2008; 2: 60–63.

39. van der Heijde D, Dijkmans B, Geusens P et al. Efficacy and safety of infliximab in patients with ankylosing spondilitis. Results of a randomized, placebo controlled trial (ASSERT). Arthritis Rhum. 2005; 52: 582–591.

40. Румянцева О.А., Бочкова А.Г., Логинова Е.Ю. и др. Исследование эффективности, безопасности и переносимости инфликсимаба у больных анкилозирующим спондилитом (предварительные результаты). Научно–практическая ревматология. 2006; 4: 11–20.

41. Chaturvedi V.P. Pilot study of chimeric monoclonal antitumor necrosis factor alpha anti body (infliximab) with methotrexate in polyarticular juvenile idiopathic arthritis. Am. College of Rheumatology 66th Annual Scientific Meeting, October 24–25. 2002. New Orleans. Abstract LB12.

42. Masatlioglu S., Gogus F., Cevirgen D. et al. Infliximab in the treatment of refractory juvenile idiopathic arthritis. Arthritis Rheum. 2002; 46: 481.

43. Crandall W.V., Mackner L.M. Infusion reactions to infliximab in children and adolescents: frequency, outcome and predictive model. Aliment. Pharmacol. Ther. 2003; 17: 75–84.

44. Gerloni V, Pontikaki I, Gattinara M, et al. Efficacy of repeated intravenous infusions of an anti–TNF–α monoclonal antibody (infliximab) in persistently active refractory juvenile idiopathic arthritis. Results of an open label prospective study. Arthritis Rheum. 2005; 52: 548–553.

45. Годзенко А.А. Антицитокиновая терапия серонегативных спондилоартритов. Трудный пациент. 2006; 5.

46. Румянцева О.А, Кузин А.В., Бунчук Н.В. Применение ремикейда при анкилозирующем спондилоартрите. Клиническая фармакология и терапия. 2004; 13 (1): 89–93.

47. Vougiouka O., Rizou S., Grafakou O. Infliximab and etanercept in the treatment of juvenile idiopathic arthritis. The Athens experience. Ann. Rheum. Dis. 2001. 60: 17–52.

48. Doran M.F., Crowson C.S., Pond G.R. et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population based study. Arthritis Rheum. 2002; 46: 2287–2293.

49. Kroesen S., Widmer, A.F., Tyndall A., Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti–TNF–alpha therapy. Rheumatology (Oxford). 2003; 42: 617.

50. Crum, NF, Lederman, ER, Wallace, MR. Infections associated with tumor necrosis factor alpha antagonists. Medicine (Baltimore). 2005; 84: 291.

51. Gomez–Reino J.J., Carmona L., Valverde V.R. et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active surveillance report. Arthritis Rheum. 2003; 48: 2122.

52. Listing J., Strangfeld A., Kary S. et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005; 52: 3403.

53. Curtis J.R., Patkar N., Xie A. et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 2007; 56: 1125.

54. Curtis J.R., Xi J., Patkar N. et al. Drug specific and time–dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 2007; 56: 4226.

55. Dixon W.G., Watson K., Lunt M. et al. Rates of serious infection, including site–specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006; 54: 2368.

56. Wolfe F., Caplan L., Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalisation for pneumonia: associations with prednisone, disease modifying antirheumatic drugs, and antitumor necrosis factor therapy. Arthritis Rheum. 2006; 54: 628–634.

57. Askling J., Fored C.M., Brandt L. et al. Time dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann. Rheum. Dis. 2007; 66: 1339–1344.

58. Dixon W.G. Symmons D.P. Lunt M. et al. Serious infection following antitumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum. 2007; 56: 2896–2904.

59. van der Heijde D., Dijkmans B., Geusens P. et al. Efficacy and safety of infliximab in patients with ankylosing spondilitis. Results of a randomized, placebo controlled trial (ASSERT). Arthritis Rhum. 2005; 52: 582–591.

60. Braun J., Brandt J., Listing J. et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002; 359: 1187–1193.

61. Козлов Р.С., Якушин С.Б., Насонов Е.Л. Инфекционные осложнения терапии блокаторами фактора некроза опухоли: предупрежден – значит вооружен. Клиническая микробиология и антимикробная химиотерапия. 2006; 8: 314–324.

62. Keane J., Gershon, S., Wise, R.P. et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha neutralizing agent. N. Engl. J. Med. 2001; 345:1098.

63. Brassard P., Kezouh A., Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin. Infect. Dis. 2006; 43: 717.

64. Wallis R.S., Broder M.S., Wong J.Y. et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis. 2004; 38: 1261.

65. Wolfe F., Michaud K., Anderson J., Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 2004; 50: 372–399.

66. Dixon W.G., Hyrich K.L., Watson K.D. et al. Drug specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti–TNF therapy: results from the BSP biologics register (BSRBR). Ann. Rheum. Dis. 2008; 67: (Suppl. II): 178.

67. Askling J., Fored C.M., Brandt L. et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005; 52 (7): 1986–1992.

68. Насонов Е.Л., Козлов Р.С., Якушин С.Б. Инфекционные осложнения терапии блокаторами фактора некроза опухоли: предупрежден — значит вооружен. Клиническая микробиология и антимикробная химиотерапия. 2006; 4: 1–11.

69. Flynn J.L., Goldstein M.M., Chan J. et al., Tumor necrosis factor–alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity. 1995; 2: 561–572.

70. Hyrich K.L., Silman A.J., Watson K.D., Symmons D. Antitumor necrosis factor a therapy in rheumatoid arthritis: an update on safety. Ann. Rheumatic. Disease. 2004; 63 (12): 1538–1543.

71. Keane J., Gershon S., Wise R. Tuberculosis associated with infliximab, a tumor necrosis factor a neutralizing agent. New Engl. J. Med. 2001; 345: 1098–1104.

72. Braun J., Pham T., Sieper J. et al. International ASAS consensus statement for the use of anti-tumor necrosis factor agents in patients with ankylosing spondilitis. Ann. Rheum. Dis. 2003; 62: 817–824.

73. Ehlers S. Why does tumor necrosis factor targeted therapy reactivate tuberculosis? J. Rheumatol. 2005: 32 (Suppl. 74): 35–39.

74. Baum J. Infection in rheumatoid arthritis. Arthr. Rheum. 1971; 14: 135–137.

75. Antolin J., Azahara M., Hernandez C. et al. Tuberculous peritonitis after treatment with adalimumab. Scand. J. Infect. Dis. 2008; 40: 677–678.

76. Fleischmann R., Iqbal I., Nandeshwar P. et al., Safety and efficacy of disease–modifying anti–rheumatic agents: focus on the benefits and risk of etanercept. Drug. Saf. 2002; 25: 173–197.

77. Gomez–Reino J.J., Carmona L., Valverde V.R. et al., Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active surveillance report. Arthritis Rheum. 2003, 48, 2122–2127.

78. Wallis R.S., Broder M.S., Wong J.Y., et al. Granulomatous infectious diseases associated with TNF antagonists. Clin. Infect. 2004; 38: 1261–1265.

79. Cientifico C. Spanish experience with a registry of adverse events in biological therapy. Ann. Rheum. Dis. 2002; 61 (suppl.1): 388.

80. Wolfe F., Michaud K., Anderson J. et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthr. Rheum. 2003; 48: 537–538.

81. Лукина Г.В., Сигидин Я.А., Насонов Е.Л. Применение инфликсимаба у больных ревматоидным артритом в клинической практике (по данным Российского регистра). Терапевтический архив. 2009; 8: 1–5.

82. Klareskog L., Moreland L.W., Cohen S.B. et al. The safety and efficacy of over seven years of continuous etanercept therapy in patients with rheumatoid arthritis in North America and Europe. Ann. Rheum. Dis. 2005; 64 (suppl. III): 410.

83. G.E.A.R. Rheumatoid Arthritis study group. Portuguese society for rheumatology. Tuberculosis in patients treated with anti–TNF–alpha therapy. The Portuguese experience. Ann. Rheum. Dis. 2006; 65 (suppl. II): 498.

84. Seong S.S., Choi C.B., Woo J.H. Incidence of TB in Korean patients with RA: Effects of RA itself and of TNF blockers. J. Rheumatol. 2007; 34: 706.

85. Cush J., Matteson E. FDA Advisory Committee Rewiews Safety on TNFInhibitors. URL: http:/www.rheumatology.org/research/hotline/09901tnf.html.

86. Lee J.H., Slifman N.R., Gershon S.K. et al. Life threatening histoplasmosis complicating immunotherapy with tumor necrosis factor a antagonists infliximab and etanercept. Arthr. Rheum. 2002; 46: 2565–2570.

87. Ruderman E.M., Markenson J.A. Granulomatous infections and tumor necrosis factor antagonists therapy. Ann. Rheum. Dis. 2003; 62 (suppl.1): 172–173.

88. Tubach F., Salmon D., Ravaud P. et al. Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy. Arthr. Rheum. 2009; 60: 1884–1894.

89. Dixon W.G., Hyrich K.L., Watson K.D. et al. Drug–specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti–TNF therapy. Results from the BSR biologics register (BSRBR). Ann. Rheum. Dis. 2008; 67 (suppl. II): 178.

90. Mitoma H., Horiuchi T., Tsuhamoto H. et al. Mechanisms for cytotoxic effects of anti–tumor necrosos factor agents on transmembrane tumor necrosis factor expressing cells: comparison among infliximab, etanercept and adalimumab. Arthr. Rheum. 2008; 58: 1248–1257.

91. Hamdi H., Mariette X., Godot V. et al. Inhibition of anti–tuberculosis T–lymphocyte function by tumor necrosis factor antagonists. Arthritis Res. Ther. 2006; 8: 114.

92. Saliu O.Y., Sofer C., Stein D.S. et al. Tumor necrosis factor blockers: differential effects on mycobacterial immunity. J. Infect. Dis. 2006; 194: 486–492.

93. Perez J.L., Kupper H., Spencer–Green G.T. Impact of screening for latent TB prior to initiating anti–TNF therapy in North America and Europe. Ann. Rheum. Dis. 2005; 64: 86.

94. Kavanaugh A., Tutuncu Z., Sanchez T. The TNF inhibitors in clinical use. J. Musculoskel. Med. 2005; 29–34.

95. Aggarwal R., Manadan A., Poliyedath A. et al. Study of etanercept in patients at high risk for mycobacterial tuberculosis infections. J. Rheumatol. 2009; 36: 914–917.

96. Gomez–Reino J.J., Cormona L., Descalzo M.A., Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthr. Rheum. 2007, 57, 756–761.

97. Joven B.E., Almodovar R., Galindo M. Does anti–tumour necrosis factor a treatment modify the tuberculin PPD response? Ann. Rheum. Dis. 2006; 65: 699.

98. Guidotti L.G., Ishikawa T., Hobbs M.V. et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity. 1996; 4: 25.

99. Guidotti L.G., Ando K., Hobbs M.V. et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a non cytolytic mechanism in transgenic mice. Proc. Natl. Acad. Sci USA. 1994; 91: 3764.

100. Nelson D.R., Lim H.L., Marousis C.G. et al. Activation of tumor necrosis factor–alpha system in chronic hepatitis C virus infection. Dig. Dis. Sci. 1997; 42:2487.

101. Ferri C., Ferraccioli G., Ferrari D. et al. Safety of antitumor necrosis factor alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J. Rheumatol. 2008; 35 (10): 1944–1999.

102. Marotte H., Fontanges E., Bailly F. et al. Etanercept treatment for three month is safe in patients with rheumatologic manifestations associated with hepatitis C virus. Rheumatology. 2007; 46: 97–99.

103. Mohan N. Edwards E.T., Cupps T.R. et al. Demyelination occurring during anti–tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001; 44: 2862.

104. Насонов Е.Л., Самсонов М.Ю. Новые аспекты патогенеза сердечной недостаточности: роль фактора некроза опухоли. Сердечная недостаточность. 2000; 1 (4): 139–143.

105. Mann D., McMurray J., Packer M. et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation. 2004; 109: 1594.

106. Anker S.D., Coats A.J. How to recover from renaissance? The significance of the results of recover, renaissance, renewal and attach. Int. J. Cardiol. 2002; 86: 123.

107. Gabriel S.E. Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis? Arthritis Rheum. 2008; 58: 637.

108. Насонов Е.Л. Проблема атеротромбоза в ревматологии. Вестник РАМН. 2003; 7, 6–10

109. Насонов Е.Л. Ревматоидный артрит – модель атеротромбоза. РМЖ. 2005; 13: 509–512

110. Jacobsson L.T., Turesson C., Culfe A. et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol. 2005; 32: 1213–1228.

111. Jacobsson L.T., Turesson C., Nilsson J.A. et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2007; 66: 670–675.

112. Dixon W.G., Watson K.D., Lunt M. et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to antitumor necrosis factor a therapy. Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007; 56: 2905–2912.

113. Furst D.E., Sokolove J., Greenberg J. et al. Risk of elevated liver enzyme (LFTS) with THF inhibitors in rheumatoid arthritis: analysis in 6861 patients with 22552 visits. Ann. Rheum. Dis. 2008; 67: 52.

114. Haraoui B., Keystone E. Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Curr. Opin. Rheumatol. 2006; 18: 96–100.

115. Mongey A.B., Hess E.V. Drug insight: autoimmune effects of medications – what’s new? Nat. Clin. Pract. Rheumatol. 2008; 4: 136–144.

116. van der Heijde D., Dijkmans B., Geusens P. et al. Efficacy and safety of infliximab in patients with ankylosing spondilitis. Results of a randomized, placebo controlled trial (ASSERT). Arthritis Rhum. 2005; 52: 582–591.

117. Braun J., Brandt J., Listing J. et al. Long term efficacy and safety of infliximab in the treatment of ankylosing spondilitis: an open, observational, extension study of a three month, randomized, placebo controlled trial. Arthritis Rheum. 2003; 48: 2224–2233.

118. Georgescu L., Quinn G.C., Schwartzman S., Paget S.A. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin. Arthritis Rheum. 1997; 26: 794.

119. Gridley G., McLaughlin J.K., Ekbom A. et al. Incidence of cancer among patients with rheumatoid arthritis. J. Natl. Cancer. Inst. 1993; 85: 307.

120. Ebeo C.T., Girish M.R., Byrd R.P. et al. Methotrexate induced pulmonary lymphoma. Chest. 2003; 123: 2150.

121. Askling J., Fored C.M., Baecklund E. et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann. Rheum. Dis. 2005; 64 (10): 1414–1420.

122. Geborek P., Bladström A., Turesson C. et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann. Rheum. Dis. 2005; 64: 699–703.

123. Wolfe W., Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study. Arthritis Rheum. 2007; 56: 2886.

124. Stone J.H., Holbrook J.T., Marriott M.A. et al. Solid malignancies among patients in the Wegener’s Granulomatosis Etanercept Trial. Arthritis Rheum. 2006; 54: 1608.

125. Ruperto N., Lovell D.J., Cuttica R. et al. A randomized, placebo controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007; 56: 3096–3106.

126. Lovell D.J., Ruperto N., Cuttica R. et al. Randomized trial of infliximab plus methotrexate for the treatment of polyarticular juvenile rheumatoid arthritis. American College of Rheumatology 68th Annual Scientific Meeting, October 16–21, 2004. San Antonio.

127. Вахлярская С.С., Кондратенко И.В., Бологов А.А. Инфликсимаб в терапии тяжелых форм ювенильного ревматоидного артрита у детей. Педиатрия. 2008;87 (2): 98–100.

128. Никишина И.П., Родионовская С.Р. Терапия рефрактерных вариантов ювенильного артрита. Педиатрия. 2006; 8 (2): 1300–1320.

129. Алексеева Е.И., Алексеева А.М., Бзарова Т.М., Валиева С.И., Афонина Е.Ю. Эффективность лечения инфликсимабом резистентных форм ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2006; 5 (2): 20–29.

130. Алексеева Е.И., Лисицин А.О., Карагулян Н.А. Адалимумаб: новые возможности лечения ювенильного артрита. Вопросы современной педиатрии. 2009; 8 (3): 88–94.


Для цитирования:


Бзарова Т., Алексеева Е., Валиева С., Алексеева А., Денисова Р., Исаева К. БЕЗОПАСНОСТЬ ПРИМЕНЕНИЯ ИНГИБИТОРОВ ФАКТОРА НЕКРОЗА ОПУХОЛИ ВО ВЗРОСЛОЙ И ДЕТСКОЙ РЕВМАТОЛОГИЧЕСКОЙ ПРАКТИКЕ. Вопросы современной педиатрии. 2010;9(1):82-94.

For citation:


Bzarova T., Alexeeva E., Valieva S., Alekseeva A., Denisova R., Isaeva K. SAFETY OF TUMOR NECROSIS FACTOR BLOCKERS IN ADULT’S AND CHILDREN’S RHEUMATOLOGIC PRACTICE. Current Pediatrics. 2010;9(1):82-94.

Просмотров: 289


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)